A review in the journal Lupus examines treatments for primary and secondary thromboprophylaxis in patients with anti-phospholipid autoantibodies (aPL) and a history of thrombosis, which can affect more than 50 percent of people with systemic lupus erythematosus.
Gregory M. Weiss, M.D.
In a review that examines the use of conventional and orphan autoantibodies as biomarkers for diagnosing systemic lupus erythematosus (SLE), researchers say the science is advancing rapidly with the goal of diagnosing lupus earlier than currently done.
Long-term remission in rheumatoid arthritis is rare, but achieving rheumatoid arthritis remission even once can improve function and quality of life, researchers report.
In the September issue of The Lancet Rheumatology, Drs. Janet Pope and Peter C. Taylor review three historical game changers in rheumatoid arthritis treatment.
Rheumatoid arthritis patients who achieve low disease activity on tofacitinib in combination with methotrexate, should be able to discontinue methotrexate safely and without significant worsening of disease activity, especially if they are having trouble tolerating it, new research shows.
When considering the evidence, it appears that rather than it being a discrete clinical entity with a unique cause, rheumatoid arthritis (RA) is likely a syndrome that represents a common endpoint for a number of different causative agents.
Low-dose interleukin-2 (IL-2) was found to be safe and well tolerated in a phase 1 and 2a trial of 12 patients with systemic lupus erythematosus (SLE). The treatment may be beneficial in reducing disease activity, researchers report in Sept. 1 issue of The Lancet Rheumatology.
A new study published in the journal Arthritis & Rheumatology finds there may be a genetic explanation for the development of systemic lupus erythematosus (SLE) in African American women.
Updated treatment recommendations have been issued for ankylosing spondylitis and non-radiographic axial spondyloarthritis. There are 86 recommendations. In this slideshow, we highlight those categorized as "strongly recommended."
Review shows inconsistencies in infliximab concentrations for patients with spondyloarthritis. More research is needed to determin optimal dosages to achieve a clinical response in spondyloarthritis.